| Abstrakt: |
Objectives: Sclerostin is a soluble regulatory factor of bone formation through inhibiting canonical Wnt signaling pathway. Recent research indicated that sclerostin might be involved in mineral and bone metabolism, however whether sclerostin play any potential role in chronic kidney disease-mineral and bone disorder was still uncertain. This study aimed to explore the relationship between circulating sclerostin levels and mineral disorders, especially secondary hyperparathyroidism in prevalent hemodialysis patients. Methods: 175 prevalent hemodialysis patients were enrolled from April to October in 2014. Clinical and biochemical data were collected. Serum sclerostin levels were measured by ELISA. Secondary hyperparathyroidism was determined as serum iPTH level above nine times upper normal limit. Results: The median serum sclerostin level was 160.50 pmol/L (interquartile range 100.67-256.39 pmol/L) in prevalent hemodialysis patients. Univariate correlation showed serum sclerostin levels positively correlated with age, BMI, serum calcium, 25(OH)VitD levels, and negatively with spKt/V and iPTH levels. Serum sclerostin levels were significantly lower in patients with secondary hyperparathyroidism. Forward logistic regression analysis showed that age (OR = 0.937, 95% CI = 0.900-0.977, p = 0.002), dialysis vintage (OR = 1.011, 95% CI = 1.002-1.019, p = 0.015), AKP (OR = 1.023, 95% CI = 1.012-1.035, p < 0.001), serum phosphate levels (OR = 3.118, 95% CI = 1.028-9.460, p = 0.045), serum calcium (OR = 13.421, 95% CI = 1.245-144.727, p = 0.032), lgSclerostin levels (OR = 0.077, 95% CI = 0.011-0.560, p = 0.011) were the independent risk factors for the presence of secondary hyperparathyroidism in prevalent hemodialysis patients. Conclusions: Decreased level of serum sclerostin was an independent risk factor for secondary hyperparathyroidism in prevalent hemodialysis patients. [ABSTRACT FROM AUTHOR] |
